The purpose of the study is to assess how effective, safe, and tolerable the fecal microbiota capsules are over a period of 72 weeks. Participants will take the capsules orally, and their liver health will be monitored throughout the study. The study aims to see if the treatment can resolve NASH without worsening liver fibrosis, which is the thickening and scarring of liver tissue. Additionally, the study will look at changes in liver inflammation, fat content in the liver as measured by MRI, and other health markers.

Participants will be observed for any side effects or changes in their health during the study. The trial will also track improvements in liver inflammation and other health indicators, such as insulin resistance and cholesterol levels. The study is designed to provide valuable information on whether this new treatment can be a safe and effective option for people with NASH.

Participants in the study will receive either efinopegdutide or a placebo, which is a substance with no active medication. The study will last for 28 weeks, during which the changes in liver fat content will be monitored. The study will also track any side effects experienced by participants and whether any participants discontinue the treatment due to these effects. The goal is to understand how efinopegdutide affects liver health and its safety for patients with MASH.

Throughout the study, various health indicators will be measured, including changes in liver stiffness and body weight. These measurements will help researchers determine the overall impact of efinopegdutide on liver health. The study aims to provide valuable insights into the potential benefits and risks of using efinopegdutide for treating MASH-related liver conditions.

Participants in the study will be randomly assigned to receive either Lanifibranor or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the initial phase. After this phase, there will be an extension period where all participants will receive the active treatment to further assess the safety of Lanifibranor.

The study will take place over a period of time, with regular check-ups and assessments to monitor the participants’ liver health and overall well-being. The main goal is to see if Lanifibranor can help resolve NASH and improve liver fibrosis, which will be evaluated through liver tissue samples. Participants will be closely monitored to ensure their safety throughout the study.

The study medication resmetirom is taken as a film-coated tablet by mouth once daily. Participants will receive either resmetirom at doses of 60 mg, 80 mg, or 100 mg, or a placebo. The study aims to determine if resmetirom can help resolve NASH and prevent the progression of liver damage. The treatment period lasts for approximately 54 months, during which participants will have regular check-ups to monitor their liver health.

Throughout the study, doctors will use various methods to assess how well the treatment is working, including examining liver tissue samples and using specialized imaging called MRI-PDFF to measure liver fat content. They will also monitor the levels of various substances in the blood that can indicate liver health and track any changes in LDL cholesterol levels. After the main study period, some participants may have the opportunity to continue treatment in a long-term extension phase.

Participants in the study will receive either semaglutide or a placebo, which is a substance with no active medication. The treatment is given as an injection under the skin using a pre-filled pen. The study is divided into two parts. In the first part, researchers will look at whether semaglutide can improve liver tissue health over a period of 72 weeks. In the second part, they will assess if semaglutide can reduce the risk of liver-related health issues over a longer period of 240 weeks.

The study will monitor various health indicators, including changes in liver tissue, body weight, and other health markers, to determine the effectiveness of semaglutide. Participants will be followed up regularly to track their progress and any changes in their condition. The goal is to gather information on whether semaglutide can be a beneficial treatment for people with NASH, potentially improving their liver health and reducing the risk of further liver damage.

The purpose of the study is to determine if the combination of NNC0194-0499 and Semaglutide can improve liver fibrosis, which is the scarring of liver tissue, in people with NASH. Participants in the study will receive weekly injections for a period of 52 weeks. The study will monitor changes in liver health, including improvements in liver fibrosis and the resolution of steatohepatitis, which is the inflammation of the liver due to fat accumulation.

Throughout the study, participants will be closely monitored to assess any changes in their liver condition and overall health. The study aims to provide valuable information on whether these medications can be an effective treatment option for people with NASH, potentially leading to better management of this liver disease. The trial is designed to ensure the safety and well-being of all participants while gathering important data on the effectiveness of the treatment.

Participants in the study will receive either the AZD2693 injection or a placebo injection. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for about a year, during which participants will be monitored for any changes in their liver condition, specifically looking for improvements in liver inflammation and scarring.

The main goal is to see if AZD2693 can help resolve NASH without worsening liver fibrosis. Secondary goals include assessing whether there is an improvement in liver fibrosis and overall liver health. Participants will undergo various assessments, including liver biopsies, to evaluate the effects of the treatment. The study aims to provide valuable information on the potential benefits of AZD2693 for people with NASH and liver fibrosis who carry the PNPLA3 genetic marker.

Participants in the study will receive either Efruxifermin or a placebo, which is a substance with no active medication. Efruxifermin is given as a solution for injection, meaning it is administered through a needle under the skin. The study will last for about 52 weeks, during which participants will have regular check-ups to monitor their liver health and overall well-being. The main goal is to see if Efruxifermin can help resolve NASH/MASH and reduce fibrosis by the end of the study period.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving Efruxifermin and who is receiving the placebo. This helps ensure that the results are unbiased. The trial will also evaluate the safety of Efruxifermin, looking at any side effects that may occur. By the end of the study, researchers hope to determine if Efruxifermin is an effective treatment option for people with NASH/MASH and fibrosis.

The purpose of the study is to assess how effective, safe, and tolerable the fecal microbiota capsules are for patients with NASH over a period of 72 weeks. Participants will be randomly assigned to receive either the fecal microbiota capsules or a placebo. Throughout the study, participants will have regular check-ups to monitor their liver health and overall well-being. The study aims to see if the treatment can help resolve NASH without worsening liver fibrosis, which is the thickening and scarring of liver tissue.

Participants will also be monitored for any side effects or changes in their health during the study. The study will look at various health indicators, such as liver inflammation, fibrosis, and other health markers, to determine the treatment’s impact. The trial is expected to provide valuable information on whether this new treatment can be a safe and effective option for people with NASH.

The purpose of the study is to assess the safety and tolerability of AZD4831 in adults with NASH who do not have cirrhosis but do have liver fibrosis, which is a type of scarring. The study will also look at how the body processes the drug. Participants will be randomly assigned to receive either AZD4831 or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will last for about 12 weeks, during which time participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, participants will have their liver function and other health markers checked to see how they change over time. The main focus will be on changes in liver enzymes, which are indicators of liver health. The study aims to provide valuable information on the potential benefits and safety of AZD4831 for people with NASH, which could lead to new treatment options for this condition in the future.

Participants in the study will receive either efinopegdutide or a placebo through subcutaneous injection, which means the injection is given under the skin. The study will last for about a year, during which the safety and tolerability of efinopegdutide will also be assessed. The main goal is to see if the treatment can help resolve NASH without making fibrosis worse. Additionally, the study will monitor any changes in body weight and any adverse events, which are unwanted effects that might occur during the study.

This trial is important for understanding how effective efinopegdutide is in treating NASH and ensuring it is safe for use. Participants will be closely monitored throughout the study to gather information on how well the treatment works and any side effects that may arise. The results of this study could provide valuable insights into new treatment options for people with NASH.

Participants in the study will receive the treatment and be monitored over a period of time to observe changes in their health. The study will look at how the body processes very low-density lipoproteins (VLDL) and triglycerides, which are types of fats in the blood, before, during, and after weight loss. Researchers will also examine other health indicators, such as insulin resistance, which is how well the body uses insulin, and various markers of inflammation, which is the body’s response to injury or infection.

The study will track changes in these health indicators over several months, comparing results from the beginning of the study to those after weight loss has stabilized. This will help researchers understand the relationship between weight loss and improvements in liver health and overall metabolism. The findings could provide valuable insights into managing obesity and NAFLD more effectively.

Participants in the study will receive either Efruxifermin or a placebo, which is a substance with no active medication. The treatment is given as a solution for injection under the skin. The study will monitor participants over a period to see if Efruxifermin can improve liver health by reducing scarring and preventing the disease from getting worse. The main goal is to see if the treatment can help people live longer without experiencing serious liver-related problems.

The study will last for several years, with regular check-ups to assess the health of the liver and overall well-being of the participants. The researchers will look at various health markers, including liver function tests and other indicators of liver health, to determine the effectiveness of Efruxifermin compared to the placebo. This research is important for understanding how to better treat liver diseases like NASH and MASH and improve the quality of life for those affected.

The purpose of this research is to determine if Namodenoson can improve the condition of patients with NASH who have mild to moderate scarring of the liver (fibrosis). The medication being studied is a synthetic substance that works by interacting with specific receptors in the body called adenosine A3 receptors.

The study will last 36 weeks, during which participants will take either Namodenoson capsules or placebo capsules daily. Throughout the study, participants will have their liver health monitored through various medical examinations. The maximum daily dose of Namodenoson that participants may receive is 50 mg. The study is designed to evaluate both how well the medication works and how safe it is for patients with NASH.